

Amaia Lujambio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735322/publications.pdf>

Version: 2024-02-01

87
papers

8,047
citations

159525

30
h-index

85498

71
g-index

91
all docs

91
docs citations

91
times ranked

13210
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
2	Imaging for better responses to immunotherapy in hepatocellular carcinoma. <i>Hepatology</i> , 2023, 77, 6-9.	3.6	1
3	The portrait of liver cancer is shaped by mitochondrial genetics. <i>Cell Reports</i> , 2022, 38, 110254.	2.9	10
4	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. <i>Cell Stem Cell</i> , 2022, 29, 298-314.e9.	5.2	23
5	Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 814120.	1.3	3
6	Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. <i>Cancers</i> , 2022, 14, 78.	1.7	3
7	ÅŸ-catenin is a novel target in YAP-driven cholangiocarcinoma. <i>Gastroenterology</i> , 2022, , .	0.6	0
8	Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy. <i>Journal of Hepatology</i> , 2022, 77, 593-595.	1.8	5
9	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. <i>Nature Medicine</i> , 2022, 28, 1599-1611.	15.2	185
10	Liver metastases inhibit immunotherapy efficacy. <i>Nature Medicine</i> , 2021, 27, 25-27.	15.2	20
11	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
12	Turning up our understanding of liver cancer by a notch. <i>Journal of Hepatology</i> , 2021, 74, 502-504.	1.8	3
13	Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 642958.	2.2	12
14	The Endless Sources of Hepatocellular Carcinoma Heterogeneity. <i>Cancers</i> , 2021, 13, 2621.	1.7	15
15	Diverse immune response of DNA damage repair-deficient tumors. <i>Cell Reports Medicine</i> , 2021, 2, 100276.	3.3	12
16	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , 2021, 27, 851-861.	15.2	38
17	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	1.5	15
18	Manipulating and tracking single hepatocyte behavior during mouse liver regeneration by performing hydrodynamic tail vein injection. <i>STAR Protocols</i> , 2021, 2, 100440.	0.5	3

#	ARTICLE	IF	CITATIONS
19	Dissecting Early Relapse in Liver Cancer, One Cell at a Time. <i>Hepatology</i> , 2021, 74, 2891-2893.	3.6	0
20	Nuclear factor erythroid 2-related factor 2 and β -Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. <i>Hepatology</i> , 2021, 74, 741-759.	3.6	32
21	An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKI-resistant cells by modulating miR-335 expression. <i>ELife</i> , 2021, 10, .	2.8	7
22	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
23	A Novel Long Noncoding RNA Finetunes the DNA Damage Response in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 4899-4900.	0.4	2
24	Decoding therapy resistance in liver tumours: a giant leap. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, , .	8.2	0
25	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	1.7	17
26	Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2020, 159, 2203-2220.e14.	0.6	47
27	Novel patient-derived preclinical models of liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 239-249.	1.8	41
28	Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. <i>Cancer Cell</i> , 2020, 37, 584-598.e11.	7.7	96
29	Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5276-5286.	3.2	13
30	Abstract LB-329: Pancancer proteomic investigation identifies overexpressed kinases as novel cancer dependent targets. , 2020, , .		0
31	Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity. , 2020, , .		0
32	Experimental Models for Preclinical Research in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 333-358.	0.4	7
33	Epigenetic Compensation Promotes Liver Regeneration. <i>Developmental Cell</i> , 2019, 50, 43-56.e6.	3.1	49
34	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1506-1519.	1.9	16
35	β -Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
36	Hepatocellular carcinoma: killing one bird with two stones. <i>Gut</i> , 2019, 68, 1543-1544.	6.1	3

#	ARTICLE	IF	CITATIONS
37	Iron overload and liver cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 723-724.	4.2	12
38	Functional screening to identify senescence regulators in cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 17-24.	1.5	5
39	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2990.	2.2	14
40	The more (mutations), the better. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	0
41	Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity. <i>Blood</i> , 2019, 134, 727-727.	0.6	18
42	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 317-325.	1.7	12
43	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	13.5	96
44	Precision medicine in a dish. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	1
45	A new hope for <i>KRAS</i> mutant cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	1
46	A (synthetic) lethal weapon for cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0
47	Unsplicing senescence. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0
48	One hepatocyte, two malignant fates. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0
49	The two immune sides of obesity. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0
50	Histone Acetyltransferase Activity of MOF Is Required for <i>MLL-AF9</i> Leukemogenesis. <i>Cancer Research</i> , 2017, 77, 1753-1762.	0.4	38
51	USP39 Deubiquitinase Is Essential for <i>KRAS</i> Oncogene-driven Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 4164-4175.	1.6	37
52	Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF- β Pathway. <i>Cell Reports</i> , 2017, 18, 2480-2493.	2.9	135
53	Therapeutic editing of hepatocyte genome in vivo. <i>Journal of Hepatology</i> , 2017, 67, 818-828.	1.8	17
54	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 1286-1296.	6.1	198

#	ARTICLE	IF	CITATIONS
55	DNA sensing in senescence. <i>Nature Cell Biology</i> , 2017, 19, 1008-1009.	4.6	18
56	Strategies for HCC target discovery. <i>Aging</i> , 2017, 9, 1088-1089.	1.4	5
57	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 45-64.	0.1	1
58	Uncovering the role of USP54 in cancer. <i>Oncotarget</i> , 2017, 8, 10765-10766.	0.8	5
59	Abstract 4393: Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis. , 2017, , .		0
60	Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors. , 2017, , .		0
61	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. <i>Gastroenterology</i> , 2016, 151, 1192-1205.	0.6	103
62	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. <i>Cancer Cell</i> , 2016, 30, 485-498.	7.7	130
63	To clear, or not to clear (senescent cells)? That is the question. <i>Inside the Cell</i> , 2016, 1, 87-95.	0.4	2
64	To clear, or not to clear (senescent cells)? That is the question. <i>BioEssays</i> , 2016, 38, S56-64.	1.2	88
65	A combinatorial strategy for treating KRAS-mutant lung cancer. <i>Nature</i> , 2016, 534, 647-651.	13.7	337
66	Abstract 2694: Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. , 2016, , .		0
67	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	7.7	128
68	The usual SASPects of liver cancer. <i>Aging</i> , 2015, 7, 348-349.	1.4	4
69	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. <i>Genes and Development</i> , 2014, 28, 1800-1814.	2.7	167
70	Splicing regulator SLU7 is essential for maintaining liver homeostasis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2909-2920.	3.9	55
71	Abstract 2935: RNAi screen identifies therapeutic targets in hepatocellular carcinoma. , 2014, , .		0
72	Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition of Apoptosis. <i>Blood</i> , 2014, 124, 3009-3009.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Non-Cell-Autonomous Tumor Suppression by p53. <i>Cell</i> , 2013, 153, 449-460.	13.5	603
74	Epigenetic disruption of cadherin-11 in human cancer metastasis. <i>Journal of Pathology</i> , 2012, 228, 230-240.	2.1	60
75	The microcosmos of cancer. <i>Nature</i> , 2012, 482, 347-355.	13.7	993
76	Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. <i>PLoS ONE</i> , 2011, 6, e21382.	1.1	38
77	Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. <i>Epigenetics</i> , 2011, 6, 1344-1353.	1.3	16
78	CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. <i>Oncogene</i> , 2010, 29, 6390-6401.	2.6	183
79	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , 2009, 19, 438-451.	2.4	218
80	How epigenetics can explain human metastasis: A new role for microRNAs. <i>Cell Cycle</i> , 2009, 8, 377-382.	1.3	143
81	CpG Island Hypermethylation, miRNAs, and Human Cancer. , 2008, , 367-384.		0
82	A microRNA DNA methylation signature for human cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13556-13561.	3.3	990
83	CpG Island Hypermethylation of Tumor Suppressor microRNAs in Human Cancer. <i>Cell Cycle</i> , 2007, 6, 1454-1458.	1.3	170
84	Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells. <i>Cancer Research</i> , 2007, 67, 1424-1429.	0.4	883
85	Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16, Activation of the DNA Damage Response Pathway. <i>Neoplasia</i> , 2007, 9, 840-IN12.	2.3	86
86	CpG island hypermethylation of tumor suppressor microRNAs in human cancer. <i>Cell Cycle</i> , 2007, 6, 1455-9.	1.3	98
87	Metastasis Genes: Epigenetics. , 0, , 85-95.		0